🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against superbug strains of the bacteria, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are escalating worldwide, with data suggesting over 82 million infections each year. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the face of growing infection rates, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is employed against UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on results published in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which involves a dual-drug approach. The trial involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians directly involved have shared positive views. The availability of a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is deemed vital to lessen the impact of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.